CIBMTR

NEW: CIBMTR Research Ibrutinib versus allogeneic HCT in relapsed/refractory del(17p) CLL/SLL Read more: 🔗pubmed.ncbi.nlm.nih.gov/4267…

🔬 27 abstracts. 14 orals. 13 posters. 298 authors from 85 institutions. At #ASH26 (Dec. 12–14), CIBMTR will showcase research on expanding donor options, safer transplants, better AML MRD testing and real-world CAR T outcomes. See the schedule: cibmtr.org/CIBMTR/About/News…

NEW: CIBMTR Research Phase II study of posttransplant cyclophosphamide-based GVHD prophylaxis after HLA-mismatched unrelated donor reduced intensity transplantation: Results from the ACCESS trial expansion cohort Read more: 🔗 pubmed.ncbi.nlm.nih.gov/4267…

Infections are common after CAR-T cells for multiple myeloma. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summaries…

NEW: CIBMTR Research Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A CIBMTR analysis Read more: 🔗pubmed.ncbi.nlm.nih.gov/4277…

NEW: CIBMTR Research Group sequential clinical trial designs for composite endpoints incorporating recurrent and terminal events Read more: 🔗pubmed.ncbi.nlm.nih.gov/4249…

Some medicines given after transplant have unique effects. Read about this BMT CTN study to learn more: cibmtr.org/Patient-Summaries…

Just published: The November 2026 Newsletter from CIBMTR. Explore insights on kidney health in transplantation, working committee updates, new data resources, and recent research advances in HCT and cellular therapy. cibmtr.org/CIBMTR/About/News…

New: CIBMTR Research Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome following axicabtagene ciloleucel or brexucabtagene CAR-T: CIBMTR research data Read more: 🔗pubmed.ncbi.nlm.nih.gov/4253…

New: CIBMTR Research GRIMM-II: A two-stage real-time algorithm for nine-locus HLA imputation and matching with up to three mismatches Read more: 🔗pubmed.ncbi.nlm.nih.gov/4257…

New: CIBMTR Research Challenges with expansion of cell and gene therapy: A call for system-level action Read more: 🔗pubmed.ncbi.nlm.nih.gov/4258…

JUST PUBLISHED TODAY: GVHD prophylaxis shapes T cell biology and immune reconstitution after HCT. Explore the latest @BMTCTN research here: science.org/doi/10.1126/scit… #HCT #GVHD #Research #CIBMTR #BMTCTN

🚨 Secure your spot at #Tandem27! Join HCT, cellular therapy, and gene therapy professionals for cutting-edge science, expert education, and valuable networking. Orlando, FL | 📅 Feb. 17-20, 2027 Register: tandemmeetings.com/Registrat…

New: CIBMTR Research Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: Results from the ACCESS trial Read more: 🔗 pubmed.ncbi.nlm.nih.gov/4261…

New: BMT CTN Research Donor-specific transplant outcomes from BMT CTN 1702: A multicenter prospective biologic assignment trial Read more: 🔗pubmed.ncbi.nlm.nih.gov/4226…

Looking to learn, connect, and collaborate? #Tandem27 brings together the HCT and cellular therapy community for four days of education, networking, and discovery. 📍 Orlando, FL | 📅 Feb. 17-20, 2027 Register: tandemmeetings.com/Registrat…

New: BMT CTN Research Patient-reported outcomes in clinical trials: Lessons from the BMT CTN Read more: 🔗pubmed.ncbi.nlm.nih.gov/4264…

🚨Last chance! Abstract submissions for the 2027 Tandem Meetings close tonight at 11:59 p.m. CT. If you've been putting finishing touches on your research, now's the time to submit for your chance to present. 📍Orlando, FL | Feb. 17-20, 2027 🔗tandemmeetings.com/Abstracts…

NEW: BMT CTN Research Interpreting cord blood transplant outcomes in BMT CTN 1702 Read more: 🔗pubmed.ncbi.nlm.nih.gov/4264…